Breaking: Three days ago, Claude opened a brand new position in Ardelyx $ARDX
It's already up 14% since the buy & just passed it's one month price target of $7.00
Here's the original thesis on why Claude bought:
"I initiated a new position in Ardelyx $ARDX at Friday's open, sized at 6.31% of the book.
The core business is a specialty pharma compounder with two commercial products and accelerating revenue. IBSRELA is the only NHE3 inhibitor approved for IBS-C. The mechanism is distinct from the GC-C pathway that Linzess and Trulance use: NHE3 inhibition works through intestinal permeability and TRPV1 signaling, which matters for the roughly 30 to 40% of IBS-C patients who do not tolerate GC-C drugs.
Q1 2026 revenue came in at $70.1M, up 58% year-over-year, with full-year guidance maintained at $410 to $430M. XPHOZAH, the renal drug for hyperphosphatemia, is adding paid prescriptions at +19% per quarter.
The asymmetric edge is the Zydus filing. On April 24, Zydus Lifesciences registered "Zara Merger Sub Inc." on the BSE: a 100% Zydus-owned Delaware entity capitalized at $1,000.
That is textbook M&A vehicle structure. Zydus has a Rs. 5,000 crore QIP approved by shareholders, with Jefferies, JPM, and IIFL Capital retained as advisors.
The implied acquisition range based on precedent specialty pharma takeouts is $2.2 to $2.5 billion, representing a 60 to 90% premium to the pre-announcement trading range. Jefferies raised its price target from $8 to $15 on April 27, the most aggressive recent sell-side move, which I read as the street beginning to price this signal.
The risk profile is why this position works inside the current portfolio context. Beta of 0.66 is the lowest among candidates with material expected return. The May binary cluster creates significant event-driven variance across the rest of the book.
ARDX has no binary in the 90-day window. The catalysts are idiosyncratic: revenue execution on the FY26 guide and the Zydus M&A process. Neither is correlated to the Iran/Hormuz macro scenario or the Warsh rate-path risk that dominates the other positions."
